INSM Insider Trading

Insider Ownership Percentage: 4.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $63,830,848.84

Insmed Insider Trading History Chart

This chart shows the insider buying and selling history at Insmed by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Insmed Share Price & Price History

Current Price: $68.57
Price Change: Price Increase of +3.76 (5.80%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for INSM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$68.57Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Insmed (NASDAQ:INSM)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INSM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$6.67Mbought$564ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4B-$2B$0$2B$4BTotal InflowsTotal Outflows
Insmed logo
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More on Insmed

Today's Range

Now: $68.57
Low: $64.35
High: $68.63

50 Day Range

MA: $76.20
Low: $64.81
High: $83.83

52 Week Range

Now: $68.57
Low: $21.92
High: $84.91

Volume

1,823,424 shs

Average Volume

2,276,898 shs

Market Capitalization

$12.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Who are the company insiders with the largest holdings of Insmed?

Insmed's top insider investors include:
  1. William Lewis (CEO)
  2. Roger Adsett (COO)
  3. Sara Bonstein (CFO)
  4. Martina MD Flammer (Insider)
  5. John Drayton Wise (Insider)
  6. Orlov S Nicole Schaeffer (Insider)
  7. Michael Alexander Smith (VP)
  8. Michael Alexander Smith (Insider)
Learn More about top insider investors at Insmed.

Who are the major institutional investors of Insmed?

Insmed's top institutional investors include:
  1. Rhumbline Advisers — 0.17%
  2. GAMMA Investing LLC — 0.04%
  3. Hennion & Walsh Asset Management Inc. — 0.02%
  4. Fulton Bank N.A. — 0.00%
  5. Versant Capital Management Inc — 0.00%
  6. NBC Securities Inc. — 0.00%
Learn More about top institutional investors of Insmed stock.

Which institutional investors are selling Insmed stock?

During the last quarter, INSM stock was sold by these institutional investors:
  1. Hennion & Walsh Asset Management Inc.
Within the last year, company insiders that have sold Insmed company stock include:
  1. William Lewis (CEO)
  2. Roger Adsett (COO)
  3. Sara Bonstein (CFO)
  4. Martina MD Flammer (Insider)
  5. John Drayton Wise (Insider)
  6. Orlov S Nicole Schaeffer (Insider)
  7. Michael Alexander Smith (VP)
Learn More investors selling Insmed stock.

Which institutional investors are buying Insmed stock?

Within the previous quarter, INSM stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Rhumbline Advisers
  3. Fulton Bank N.A.
  4. NBC Securities Inc.
  5. Versant Capital Management Inc